Blockbuster News with Blue Shield Approval: Charles Payne Report

You received this e-mail because we thought the following offer from one of our third party advertisers may interest you.

Cardiac Network Major Breaking News has Been Released! Blue Shield of California gives approval http://finance.yahoo.com/q?s=cnwi.pk Cardiac Network Shares Could Triple In Six Months Thanks to Medicare, Humana and now Blue Shield approved! (symbol: CNWI) Here's why buying Cardiac Network (OTC: CNWI) now at about $2.35 could make you richer than if you'd had a piece of Google's IPO:, Soon, many of the 75 million Americans over age 50 may carry this tiny, life-saving HeartOne device! In the next few years, this market could easily be over $1 billion My one year target on CNWI is $6.00 My two year target on CNWI is $12.00 My five year target on CNWI is $20.00 With its user-friendly digital designs, not only will Cardiac Network (OTC: CNWI) help millions of lives, it will make millions for investors who buy this $2.35 stock now. Car keys... cell phone... HeartOne®. Soon, no babyboomer will leave home without it! Buy Cardiac Network (OTC: CNWI) stock now while it's still around $2.35! The potential profit is mind boggling! Heart attack is still the leading cause of death among Americans over the age of 65. Every senior worries about having a heart attack. And for good reason. Each year, in the U.S. alone, 1.1 million people suffer a heart attack. About 460,000 of them die. BUT. . .of the 460,000 that die, an estimated... 50% might have lived if they had received early defibrillation from trained help. The most common symptom of a heart attack may be denial by the patient! Charles Payne & Wall Street Strategies I started Wall Street Strategies in 1991 to help stock brokers and individual investors get beyond tainted research and identify opportunities. Over the years our reputation and stature has grown as we have had folks from 65 countries and more than 100 different brokerage firms subscriber to one or more of our services. We take tremendous pride in our work ethic, track record and commitment to our subscribers. Our clients include individual investors as well as institutional investors. In addition to me we have a team of analysts scouring the market second to second to find ideas and make sure we are ahead of the curve with open positions. Our mission is to enhance the wealth of our clients in the stock market. We do this through a variety of services including our monthly Newsletter, and daily Hotline (for intermediate term investors) and Swing (for investors looking to generate cash by buying and holding ideas in a period of 30-days or less). We also pride ourselves on educating our clients. This year my first book was released: "Be Smart Act Fast Get Rich" which urges all Americans to be active investors in the stock market. Our methodology involves three components including fundamental, technical and behavioral analyses. The weightings of these components differ depending on the service. Our goal is to also personalize the services which is why every subscriber is assigned a representative. The stock market is an emotional and confusing place and there are times when the message from a monthly newsletter or even an email isn't enough to provide clear-headed guidance. Charles Payne Knowing when to call for help is key to survival. As many as 230,000 Americans probably die each year because they hoped it was only heartburn . . .or because they decided to wait to see if the symptoms went away. . . or because they didn't want to cause a fuss over nothing. Which explains why most of the 1.1 million Americans who suffer a heart attack each year go for hours before getting help. They wait until they collapse. That's tragic! Now. . .in only seconds, anyone can phone-transmit digital data that tells if it's time to get help! It could help your life or someone you love. With more than 75 million American over the age of 50. . .and more than half of them at increased risk of a heart attack because of diabetes, high blood pressure, high cholesterol or because they are overweight or have a family history of heart disease. . .you can see why I'm so excited about this company and it's still-undiscovered $2.35 stock! I suggest you stop everything you're doing and read my special free report on Cardiac Network Inc. CNWI right now! Learn More Get my Free Report DISCLAIMER: This publicly distributed e-mail report of Charles Payne, is a sponsored advertisement. This paid advertising issue of Charles Payne does not purport to provide an analysis of any company's financial position and is not in any way to be construed as an offer or solicitation to buy or sell any security. Charles Payne is a paid advertiser. Cardiac Network Inc.is the featured company. The distribution costs of this report to new subscribers, seventy nine thousand four hundred and forty five dollars, were funded by DML Marketing in an effort to create investor awareness of Cardiac Network, Inc. DML Marketing is not a licensed broker, broker dealer, market maker, investment banker, finacial advisor, analyst or underwriter , but could be deemed an affiliate, of the featured company insofar as friends, family members and affiliates own approximately twenty percent of the company. Licensors, affiliates, officers, directors and employees do own shares and may buy and sell additional shares of the company mentioned herein for less than the expected price given in this material. We will not advise as to if or when they should decide to buy or sell and do not offer any opinion as to when others should buy or sell. Each investor must make that decision based on his or her judgment of the market. DML Marketing can be reimbursed for advertising costs and efforts at a later date by third party shareholders. The amount is unknown. It is anticipated that this report will generate new subscriptions for Charles Payne and expect to receive an unknown amount of revenue from new subscriptions from the subscription offer contained herein. Charles Payne, the reviewer [or analyst], has been paid eight thousand dollars in compensation for preparing and publishing this report and could receive additional compensation for ongoing reviews and additional publications over the following three month period. Neither, Charles Payne is a licensed broker, broker dealer, market maker, investment banker. Charles Payne was paid $15,000 for six month contract. This report, including the opinions expressed and the statements made within, is for informational and advertising purposes only and should not be construed as specific advice and does not constitute an offer to sell any securities, and it is not soliciting an offer to buy any securities in any state or other jurisdiction where the offer or sale is not permitted. The information used to prepare this report is believed to be from reliable sources, but no representation is made as to the accuracy or completeness of such information. Participating in securities carries a high degree of risk and involves risks and uncertainties which may result in investors' losing all of their invested capital. Past performance does not guarantee future results. The information contained herein contains "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. Factors that could cause actual results to differ materially include but are not limited to adverse economic conditions, intense competition, inadequate capital, termination of contracts or agreements, adverse publicity and news coverage, inability to carry out, development plans, loss or retirement of key executives. Readers should consult with their own professional opinons, tax and portfolio advisors before making any decision and should independently verify all information herein.For additional information about Cardiac Network Inc. visit the company website by clicking here, www.cardiacnetwork.net

This is an email advertisement from TheStockAdvisors.com This is a paid advertisement provided to our customers. Although we have sent you this email, TheStockAdvisors.com does not endorse this product or company nor is it responsible for the content of this ad. Furthermore, we make no guarantee or warranty about what is advertised above, and have not independently reviewed the information provided within this advertisement. We respect your privacy and therefore this email has been sent directly from TheStockAdvisors.com. TheStockAdvisors.com does not provide our email lists and other data to third parties. This is consistent with our Privacy Policy as outlined on our web site.

TheStockAdvisors.com, has been paid a total of eleven thousand seven hundred dollars from the company shown above (or its agent) as compensation for the distribution of the advertisement shown above. The opinions represented in this email advertisement are not those of TheStockAdvisors.com. The company is not affiliated with TheStockAdvisors.com. TheStockAdvisors.com has not independently confirmed the accuracy, correctness, or truthfulness of the statements and opinions that the advertiser has expressed above or in any related reports. The advertisement is neither an offer nor solicitation to buy or sell any securities.

We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. The resources are not intended to be used as personalized investment recommendation. Please consult with your own advisor to decide if this investment is right for you. Please note that TheStockAdvisors.com does not produce or endorse this product, and assumes no responsibility for the use thereof.

If you do not wish to receive future advertisements from TheStockAdvisors.com, please follow the below unsubscribe instructions.

TheStockAdvisors.com 240 Madison Ave, 12th Floor NY, NY 10016

To unsubscribe, please click here.